Mayinglong Pharmaceutical Group Co., Ltd. (SHA:600993)
China · Delayed Price · Currency is CNY 22.50
-0.15 (-0.66%)
Sep 10, 2026, 3:00 PM CST
SHA:600993 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 9,763 | 12,070 | 11,255 | 10,423 | 9,742 | 12,397 | |
Market Cap Growth | -15.99% | 7.24% | 7.98% | 6.99% | -21.42% | 42.80% |
Enterprise Value | 7,506 | 9,656 | 8,616 | 8,279 | 7,569 | 10,698 |
Last Close Price | 22.65 | 27.20 | 24.82 | 22.65 | 20.88 | 26.16 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 16.29 | 20.76 | 21.31 | 23.52 | 20.36 | 26.68 |
Forward PE | 14.66 | 16.87 | 18.47 | 21.80 | 21.80 | 21.80 |
PS Ratio | 2.48 | 3.12 | 3.02 | 3.32 | 2.76 | 3.66 |
PB Ratio | 2.14 | 2.67 | 2.68 | 2.69 | 2.69 | 3.74 |
P/TBV Ratio | 2.27 | 2.85 | 2.85 | 2.88 | 2.84 | 3.99 |
P/FCF Ratio | 15.30 | 25.09 | 38.31 | 29.30 | 36.51 | 23.30 |
P/OCF Ratio | 13.56 | 20.10 | 22.62 | 17.26 | 28.50 | 20.76 |
PEG Ratio | - | 1.56 | 1.56 | 1.56 | 1.56 | 1.56 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.91 | 2.50 | 2.31 | 2.64 | 2.14 | 3.16 |
EV/EBITDA Ratio | 10.11 | 13.73 | 13.50 | 19.07 | 13.99 | 21.61 |
EV/EBIT Ratio | 11.21 | 14.98 | 14.68 | 21.52 | 15.32 | 23.60 |
EV/FCF Ratio | 11.76 | 20.07 | 29.33 | 23.28 | 28.36 | 20.11 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.02 | 0.02 | 0.06 | 0.07 | 0.18 | 0.06 |
Debt / EBITDA Ratio | 0.13 | 0.14 | 0.35 | 0.59 | 1.11 | 0.35 |
Debt / FCF Ratio | 0.15 | 0.21 | 0.80 | 0.77 | 2.39 | 0.34 |
Net Debt / Equity Ratio | -0.52 | -0.55 | -0.70 | -0.72 | -0.74 | -0.75 |
Net Debt / EBITDA Ratio | -3.28 | -3.55 | -4.58 | -6.40 | -4.93 | -5.04 |
Net Debt / FCF Ratio | -3.73 | -5.19 | -9.95 | -7.81 | -10.00 | -4.69 |
Asset Turnover | 0.69 | 0.73 | 0.75 | 0.63 | 0.77 | 0.85 |
Inventory Turnover | 7.47 | 6.57 | 7.25 | 6.00 | 6.27 | 6.94 |
Quick Ratio | 3.12 | 4.46 | 4.54 | 5.03 | 4.38 | 4.43 |
Current Ratio | 3.52 | 4.96 | 4.94 | 5.54 | 4.92 | 5.05 |
Return on Equity (ROE) | 14.16% | 13.90% | 13.59% | 12.07% | 13.83% | 15.14% |
Return on Assets (ROA) | 7.35% | 7.59% | 7.33% | 4.85% | 6.70% | 7.09% |
Return on Invested Capital (ROIC) | 25.86% | 33.41% | 41.33% | 32.51% | 47.99% | 49.86% |
Return on Capital Employed (ROCE) | 14.20% | 13.80% | 13.40% | 9.30% | 11.70% | 13.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 6.15% | 4.82% | 4.69% | 4.25% | 4.91% | 3.75% |
FCF Yield | 6.54% | 3.99% | 2.61% | 3.41% | 2.74% | 4.29% |
Dividend Yield | 3.04% | 2.57% | 2.50% | 1.77% | 1.68% | 1.34% |
Payout Ratio | 44.66% | 46.37% | 33.57% | 36.71% | 34.49% | 26.80% |
Buyback Yield / Dilution | -1.13% | -0.32% | 0.23% | 0.19% | -0.22% | 0.43% |
Total Shareholder Return | 1.91% | 2.25% | 2.73% | 1.95% | 1.45% | 1.76% |